热疗对晚期非小细胞肺癌化疗增效作用的临床观察  

Clinical Observation of Hyperthemia and Chemotherapy for Advanced Non-small-cell Lung Cancer

作　　者：田春桃[1] 张瑞文[1] 范慧娟[1] 陈娇红[1] 张向前[1] 苏静[1] 赵君梅[1] 

机构地区：[1]三门峡市中心医院肿瘤科,河南三门峡472000

出　　处：《肿瘤基础与临床》2013年第5期406-408,共3页journal of basic and clinical oncology

基　　金：三门峡市科技计划资助项目(编号:0801064064)

摘　　要：目的评价热疗联合化疗对晚期非小细胞肺癌(NSCLC)的临床疗效。方法晚期NSCLC患者120例随机分成热化疗组和化疗组,热化疗组采用化疗与热疗联合治疗,化疗组仅行化疗,2组病例均在治疗2周期后进行临床疗效及毒副反应评价。结果热化疗组和化疗组有效率分别为66.67%和33.39%,差异有统计学意义(P<0.05)。热化疗组生活质量改善率76.67%,化疗组为56.67%,差异有统计学意义(P<0.05);2组1 a生存率分别为55.0%、35.0%,差异有统计学意义(P<0.05)。结论热疗联合化疗治疗晚期NSCLC疗效优于单纯化疗,且不增加毒副反应,是晚期NSCLC可选择的一种安全有效的治疗方法。Objective To evaluate the clinical effect of hyperthemia and chemotherapy in the treatment of ad- vanced non-small-cell lung cancer （NSCLC）. Methods The 120 cases of advanced NSCLC were randomly divided into the thermochemotherapy group and the chemotherapy group. Sixty patients of the thermochemotherapy group were treated by hyperthermia with chemotherapy, and 60 patients of the chemotherapy group were treated by chemo- therapy alone. After 2 cycles of treatment, the clinical effect and toxicities were compared between the two groups. Results The total effective rate was 66.67% in the thermochemotherapy group, and was 33.39% in the chemo- therapy group （ P 〈 0.05 ）. The improvement rate of quality of life was 76.67% in the thermochemotherapy group, and was 56.67% in the chemotherapy group （ P 〈 0.05）. The 1-year survival rate was 55.0% in the thermochemo- therapy group, and was 35.0% in the chemotherapy group （ P 〈 0.05 ）. Conclusion Thermochemotherapy can im- prove the clinical effect of advanced NSCLC, and the toxicities are tolerated too.

关 键 词：热疗 化疗 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤] R730.58[医药卫生—临床医学]